Citi analyst Geoff Meacham raised the firm’s price target on Gilead (GILD) to $135 from $125 and keeps a Buy rating on the shares. Citi’s survey ...
“We already have the tools to end HIV: the science, the medication, and the technology. What’s missing is the will, the ...
Gilead Sciences, Inc., GILD announced that it has entered into settlement agreements to resolve the patent litigations with a ...
Taking an HIV drug? Slashing those costs is more doable than you think. Let’s break down five powerhouse ways to make HIV ...
Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until ...
Gilead looks attractive again. Its innovative edge and new crop of medications are performing well across multiple ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best large cap value stocks to buy now. On September 22, Morgan Stanley ...
More than 50% of HIV diagnoses now occur in 48 counties in the United States. Cuyahoga County, home to Cleveland, is one of ...
In his first term, President Trump pledged to boost HIV spending, with the lofty goal of bringing the epidemic to heel by ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On ...
The report found that 146 new HIV diagnoses were reported in The City in 2024, a 4.3% increase from the record low in 2023 of 140 diagnoses. There were 11,552 people living with HIV in San Francisco ...